Study #2016-0713
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia
Study Status
Open
Treatment Agent
MEN1703, SEL24
Principal Investigator
Farhad Ravandi-Kashani
Description
The goal of this clinical research study is to find the highest tolerable dose of SEL24/MEN1703 that can be given to patients with acute myeloid leukemia (AML). Researchers want to learn more about the safety and potential effects of this study drug. This is the first study using SEL24/MEN1703 in humans.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: MEN1703, SEL24
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Selvita
Study Status
IRB Review and Approval Date: 01/11/2017
Recruitment Status: Open
Projected Accrual: 118
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I/Phase II
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789